Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Ming Yi, Mengke Niu, Yuze Wu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 100

Showing 1-25 of 100 citing articles:

Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 439
Recent advances in targeted strategies for triple-negative breast cancer
Shuangli Zhu, Yuze Wu, Bin Song, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 103
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
Ming Yi, Yuze Wu, Mengke Niu, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 12, pp. e005543-e005543
Open Access | Times Cited: 95
Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy
Zili Zhang, Haifeng Zhou, Xiaohu Ouyang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 90
Exploiting innate immunity for cancer immunotherapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 78
Exploiting RIG-I-like receptor pathway for cancer immunotherapy
Yangfu Jiang, Hongying Zhang, Jiao Wang, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 70
Targeting cytokine and chemokine signaling pathways for cancer therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 49
Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
Mengke Niu, Ming Yi, Yuze Wu, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 46
Polymeric STING Pro‐agonists for Tumor‐Specific Sonodynamic Immunotherapy
Jie Yu, Shasha He, Chi Zhang, et al.
Angewandte Chemie International Edition (2023) Vol. 62, Iss. 32
Closed Access | Times Cited: 44
Polysaccharides regulate Th1/Th2 balance: A new strategy for tumor immunotherapy
Qihang Shang, Xiaoyun Yu, Qi Sun, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 170, pp. 115976-115976
Open Access | Times Cited: 44
Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer
Moumita Kundu, Ramesh Butti, Venketesh K. Panda, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 38
A Hybrid Nanoadjuvant Simultaneously Depresses PD‐L1/TGF‐β1 and Activates cGAS‐STING Pathway to Overcome Radio‐Immunotherapy Resistance
Yi Lei, Xin Jiang, Zaigang Zhou, et al.
Advanced Materials (2024) Vol. 36, Iss. 15
Closed Access | Times Cited: 26
Nanomaterial-encapsulated STING agonists for immune modulation in cancer therapy
Xi Chen, Zhijie Xu, Tongfei Li, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 21
Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside
Yue Yin, Weibo Feng, Jie Chen, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 18
TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Ming Yi, Tianye Li, Mengke Niu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 53
cGAS-STING signaling in the tumor microenvironment
Ziqi Liu, Dan Wang, Jiarong Zhang, et al.
Cancer Letters (2023) Vol. 577, pp. 216409-216409
Closed Access | Times Cited: 35
Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy
Hao Yang, Zhong-Hao Ji, Hengzong Zhou, et al.
MedComm (2023) Vol. 4, Iss. 4
Open Access | Times Cited: 30
The application and research progress of anti-angiogenesis therapy in tumor immunotherapy
Jingyao Tu, Hang Liang, Chunya Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 29
Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer
Hao Zhang, Shuangli Zhu, Haiting Zhou, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 28
The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling
Tianye Li, Mengke Niu, Jianwei Zhou, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 14
STING agonist-based hydrogel enhances immune activation in synergy with radiofrequency ablation for hepatocellular carcinoma treatment
Feng Ao, Xi Li, Yan Zhi Tan, et al.
Journal of Controlled Release (2024) Vol. 369, pp. 296-308
Closed Access | Times Cited: 13
Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies
Siwei Zheng, Wenwen Wang, Lesang Shen, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 13
STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance
Tianye Li, Weijiang Zhang, Mengke Niu, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 8
A next-generation STING agonist MSA-2: From mechanism to application
Junhan Yang, Zhenyu Luo, Jingyi Ma, et al.
Journal of Controlled Release (2024) Vol. 371, pp. 273-287
Closed Access | Times Cited: 8
Enhanced Antitumor Efficacy of STING Agonist MSA-2 by Lipid Nanoparticles Delivering Circular IL-23 mRNA and Platinum-Modified MSA-2 Combination
He Tian, Yating Li, Weiqi Li, et al.
Materials Today Bio (2025) Vol. 30, pp. 101446-101446
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top